News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
263,593 Results
Type
Article (14061)
Company Profile (282)
Press Release (249250)
Section
Business (79430)
Career Advice (152)
Deals (13215)
Drug Delivery (34)
Drug Development (50381)
Employer Resources (31)
FDA (5699)
Job Trends (5120)
News (144250)
Policy (10023)
Tag
Academia (901)
Alliances (21591)
Alzheimer's disease (784)
Antibody-drug conjugate (ADC) (70)
Approvals (5686)
Artificial intelligence (90)
Bankruptcy (100)
Best Places to Work (4553)
Biotechnology (232)
Breast cancer (124)
Cancer (1049)
Cardiovascular disease (85)
Career advice (132)
CAR-T (86)
Cell therapy (250)
Clinical research (40441)
Collaboration (407)
Compensation (165)
COVID-19 (1020)
C-suite (104)
Cystic fibrosis (73)
Data (1076)
Diabetes (98)
Diagnostics (1248)
Drug discovery (65)
Earnings (29089)
Events (47511)
Executive appointments (330)
FDA (6153)
Funding (388)
Gene editing (73)
Gene therapy (188)
GLP-1 (336)
Government (1070)
Healthcare (6561)
Infectious disease (1066)
Inflammatory bowel disease (100)
IPO (7235)
Job creations (859)
Job search strategy (127)
Layoffs (194)
Legal (1381)
Lung cancer (156)
Manufacturing (97)
Medical device (2567)
Medtech (2568)
Mergers & acquisitions (6189)
Metabolic disorders (300)
Neuroscience (1085)
NextGen: Class of 2025 (2013)
Non-profit (852)
Northern California (1253)
Obesity (163)
Opinion (95)
Parkinson's disease (88)
Patents (72)
People (25286)
Phase I (14278)
Phase II (18809)
Phase III (11888)
Pipeline (468)
Postmarket research (852)
Preclinical (5985)
Radiopharmaceuticals (208)
Rare diseases (236)
Real estate (1411)
Regulatory (8385)
Research institute (932)
Series A (75)
Southern California (1126)
Startups (1968)
United States (9956)
Vaccines (183)
Weight loss (94)
Date
Today (97)
Last 7 days (389)
Last 30 days (1701)
Last 365 days (20468)
2025 (1769)
2024 (20552)
2023 (22414)
2022 (26822)
2021 (27805)
2020 (23357)
2019 (16224)
2018 (11738)
2017 (13745)
2016 (11839)
2015 (14349)
2014 (10392)
2013 (7484)
2012 (7532)
2011 (7614)
2010 (7428)
Location
Africa (147)
Asia (17046)
Australia (2884)
California (2866)
Canada (910)
China (255)
Colorado (109)
Connecticut (118)
Europe (36672)
Florida (326)
Georgia (85)
Illinois (182)
Indiana (69)
Maryland (376)
Massachusetts (2278)
Minnesota (114)
New Jersey (715)
New York (787)
North Carolina (454)
Northern California (1253)
Ohio (93)
Pennsylvania (543)
South America (207)
Southern California (1126)
Texas (319)
Washington State (274)
263,593 Results for "siamab therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Drug Development
Our Mission at Voyager Therapeutics: Define the Future of Neurogenetic Medicines
We are in an unprecedented time in neurotherapeutics. Medicines that address the causative disease biology underlying central nervous system
May 8, 2024
·
2 min read
·
Voyager Therapeutics, Inc.
Press Releases
Allogene Therapeutics Announces Participation in February Investor Conferences
February 4, 2025
·
2 min read
Press Releases
Denali Therapeutics Announces Upcoming Presentations on Hunter Syndrome (MPS II) and TransportVehicle™ Enabled Investigational Therapeutic Tividenofusp Alfa at the 2025 WORLDSymposium™
January 30, 2025
·
4 min read
Genetown
Angel-Funded Siamab Completes $202 Million Exit with Large Commercial-Stage Biopharma
Siamab Therapeutics, Inc., a biopharmaceutical company developing novel glycan-targeted cancer therapeutics, has entered into a strategic agreement valued at up to $202 million with an undisclosed, large commercial-stage biopharmaceutical company under which such company will develop and commercialize antibody-based products targeting a tumor-associated carbohydrate antigen (TACA) identified by Siamab’s proprietary TACA discovery platform.
August 19, 2019
·
3 min read
Press Releases
Outlook Therapeutics® Participates in Virtual Investor “What This Means” Segment
February 4, 2025
·
4 min read
Press Releases
Tango Therapeutics to Present at the Guggenheim SMID Cap Biotechnology Conference
January 30, 2025
·
1 min read
Press Releases
NeuroEM Therapeutics(R) Accepted into StartUp Health’s Alzheimer’s Moonshot Community(TM)
September 19, 2024
·
4 min read
Press Releases
Elevar Therapeutics Announces the Formation and Members of Scientific Advisory Board
January 27, 2025
·
5 min read
Regulatory
FDA Warns Applied Therapeutics of ‘Objectionable Conditions’ in Govorestat Study
The agency’s warning letter outlines Applied Therapeutics’ failure to provide adequate information regarding the clinical trial—including a dosing error for govorestat—claims that the company said it had already addressed.
December 4, 2024
·
2 min read
·
Tristan Manalac
Press Releases
Denali Therapeutics Announces Key Anticipated 2025 Milestones and Priorities to Further Advance Its Therapeutics Portfolio for Neurodegeneration and Lysosomal Storage Diseases
January 14, 2025
·
10 min read
1 of 26,360
Next
